

FDA FACT SHEET

TISSUE RESIDUE COOPERATIVE AGREEMENT PROGRAM

Program Description

- This program is designed for state regulatory agencies to enhance their existing tissue residue program.
- The FDA's Office of Partnerships (OP) and Center of Veterinary Medicine (CVM) have worked together to develop this cooperative agreement program. The primary focus of this initiative is education, outreach, and training.
- This program is offered to all state government agencies that have current FDA Tissue Residue Inspection Contracts or have previously been awarded an FDA Tissue Residue Inspection Contract.

Intended Outcomes

- Improved/developed state drug residue prevention programs through outreach and training.
- Increased knowledge of proper drug use.
- Developed materials or events for drug residue prevention and awareness.
- Continued support of activities related to compliance to extra-label drug use regulations.
- Awareness of proper use of antimicrobial drugs in food-producing animals.
- Ensure current drug residue prevention programs are developed to reduce outcomes of illegal drug residues in animal derived food and protect consumer exposure to drug residues in edible products of food animal.

Program Metrics

- Current program funding: \$731,020.00
- Current number of awards: 7
- Current partners: Iowa, Kansas, Minnesota, North Dakota, New York, Virginia, Vermont

Have you seen our Blog? [FDA Voice](#)



The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, and products that give off electronic radiation, and for regulating tobacco products.